Notably, HER2 overexpression (HER2+) in breast cancer is correlated with faster tumour growth and higher risk of recurrence, however, it also provides a specific target for antibody-based cancer therapy with, e.g., trastuzumab (Herceptin) [8,9,10]. This evidence concerns the gene ERBB2 and breast cancer.